Literature DB >> 22855173

EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma.

K Matušan-Ilijaš1, G Damante, D Fabbro, G Dorđević, I Hadžisejdić, M Grahovac, M Avirović, B Grahovac, N Jonjić, K Lučin.   

Abstract

AIM AND
BACKGROUND: Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase involved in many important aspects of cell biology that are related to tumorigenesis. There are opposite evidences of the role of EGFR in renal cancer and the outcome of EGFR-targeted therapies, suggesting the complexity of EGFR signaling pathways. In vitro, osteopontin (OPN) and nuclear factor kappa B (NF-κB) are thought to be involved in specific ligand-independent EGFR activation that could have a role in resistance to EGFR mAb therapy. Aim of this study was to analyze the relationship between EGFR and OPN at the protein and mRNA level, as well as their relation to NF-κB in clear cell renal cell carcinoma (CCRCC).
MATERIALS AND METHODS: Expression of EGFR, OPN, and p65 NF-κB protein was analyzed using immunohistochemistry and compared mutually in 88 CCRCC samples. Expression of EGFR and OPN mRNAs was analyzed using quantitative Real-time PCR in 22 CCRCC samples and compared mutually and with NF-κB protein expression.
RESULTS: Epidermal growth factor receptor mRNA level was higher in CCRCC samples in comparison with normal renal tissue (p = 0.012) and was associated with high OPN mRNA level, and with NF-κB activation (p < 0.001 and p = 0.045, respectively). Immunohistochemical staining showed the inverse association; high EGFR protein expression was related with low OPN and NF-κB protein expression (p < 0.001 and p = 0.047, respectively).
CONCLUSION: Epidermal growth factor receptor gene is upregulated in CRCC and associated with OPN gene expression and NF-kB signaling. The inverse relation between OPN and EGFR at the protein level could probably reflect dynamic changes that EGFR undergoes following activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855173     DOI: 10.1007/s12094-012-0889-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  36 in total

Review 1.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 2.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

Review 3.  Signal co-operation between integrins and other receptor systems.

Authors:  Charles H Streuli; Nasreen Akhtar
Journal:  Biochem J       Date:  2009-03-15       Impact factor: 3.857

4.  Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer.

Authors:  Guoxin Zhang; Bin He; Georg F Weber
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

5.  Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma.

Authors:  Koviljka Matusan; Gordana Dordevic; Darko Stipic; Vladimir Mozetic; Ksenija Lucin
Journal:  J Surg Oncol       Date:  2006-09-15       Impact factor: 3.454

6.  Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues.

Authors:  Michael Keese; Richard J Magdeburg; Torsten Herzog; Till Hasenberg; Martin Offterdinger; Rainer Pepperkok; Jörg W Sturm; Philippe I H Bastiaens
Journal:  J Biol Chem       Date:  2005-05-20       Impact factor: 5.157

7.  A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.

Authors:  Monika Jermann; Rolf A Stahel; Marc Salzberg; Thomas Cerny; Markus Joerger; Silke Gillessen; Rudolf Morant; Fritz Egli; Kaspar Rhyner; Jean A Bauer; Miklos Pless
Journal:  Cancer Chemother Pharmacol       Date:  2005-07-29       Impact factor: 3.333

8.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

Authors:  Ronald M Bukowski; Fairooz F Kabbinavar; Robert A Figlin; Keith Flaherty; Sandy Srinivas; Ulka Vaishampayan; Harry A Drabkin; Janice Dutcher; Sarah Ryba; Qi Xia; Frank A Scappaticci; David McDermott
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

9.  Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway.

Authors:  Guo-Xin Zhang; Zhi-Quan Zhao; Hong-Di Wang; Bo Hao
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

10.  Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense?

Authors:  M Nannini; M A Pantaleo; P Paterini; G Piazzi; C Ceccarelli; S La Rovere; A Maleddu; G Biasco
Journal:  Colorectal Dis       Date:  2011-05       Impact factor: 3.788

View more
  9 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Angiotensin 1-7, but not the thrombin-cleaved osteopontin C-terminal fragment, attenuates osteopontin-mediated macrophage-induced endothelial-cell inflammation.

Authors:  Rachel Hamias; Assaf Rudich; George Greenberg; Gabriel Szendro; Talya Wolak
Journal:  Inflamm Res       Date:  2017-11-27       Impact factor: 4.575

3.  The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis.

Authors:  Tao Zhang; Dong-Ming Zhang; Da Zhao; Xiao-Ming Hou; Xiao-Jun Liu; Xiao-Ling Ling; Shou-Cheng Ma
Journal:  J Mol Histol       Date:  2014-05-10       Impact factor: 2.611

4.  Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma.

Authors:  Erik Hedrick; Syng-Ook Lee; Gyungeun Kim; Maen Abdelrahim; Un-Ho Jin; Stephen Safe; Ala Abudayyeh
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

5.  Sex difference in EGFR pathways in mouse kidney-potential impact on the immune system.

Authors:  Fengxia Liu; Yan Jiao; Yun Jiao; Franklin Garcia-Godoy; Weikuan Gu; Qingyi Liu
Journal:  BMC Genet       Date:  2016-11-24       Impact factor: 2.797

Review 6.  Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.

Authors:  Yongchang Lai; Zhijian Zhao; Tao Zeng; Xiongfa Liang; Dong Chen; Xiaolu Duan; Guohua Zeng; Wenqi Wu
Journal:  Cancer Cell Int       Date:  2018-03-05       Impact factor: 5.722

7.  Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.

Authors:  Julia Schueler; Cordula Tschuch; Kerstin Klingner; Daniel Bug; Anne-Lise Peille; Leanne de Koning; Eva Oswald; Hagen Klett; Wolfgang Sommergruber
Journal:  Cells       Date:  2019-07-18       Impact factor: 6.600

8.  Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells.

Authors:  Tímea Kiss; Krisztina Jámbor; Viktória Koroknai; István Szász; Helga Bárdos; Attila Mokánszki; Róza Ádány; Margit Balázs
Journal:  Pathol Oncol Res       Date:  2021-03-05       Impact factor: 3.201

9.  Identification of key genes and pathways in human clear cell renal cell carcinoma (ccRCC) by co-expression analysis.

Authors:  Lushun Yuan; Guang Zeng; Liang Chen; Gang Wang; Xiaolong Wang; Xinyue Cao; Mengxin Lu; Xuefeng Liu; Guofeng Qian; Yu Xiao; Xinghuan Wang
Journal:  Int J Biol Sci       Date:  2018-02-12       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.